Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
Fianlimab maintains its leading activity, but more Opdualag competition is not far behind.
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
The Lag3 inhibitor is now approved in melanoma, but Bristol looks unlikely to stop there in its search for a safer Yervoy.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
The Relativity-047 study shows that relatlimab has a big safety advantage over Yervoy, with just a slight decrease in clinical benefit.